The judicial recovery plan was based on the sale of non-core assets and the biotechnology business.
Approval of the PRJ with debt discounts, as well as extension and grace period in the flow of payments in order to fit into a feasible projection of the company's cash flow.
The explicit discount in Class 2 (real guarantee) was 30% and in Class 3 (unsecured) it reached 50%. The total amount of debt negotiated totaled almost R$ 600 million.